Clinical Trial Update: Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study [Phase 3]

View source ↗

Summary

A Phase 3 COMMIT trial is evaluating the addition of atezolizumab to combination chemotherapy or atezolizumab alone for metastatic colorectal cancer; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7 | Phase 3 | Status: ACTIVE_NOT_RECRUITING